.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Ergoloid mesylates - Generic Drug Details

« Back to Dashboard
Ergoloid mesylates is the generic ingredient in eight branded drugs marketed by Kv Pharm, Novartis, Watson Labs, Sun Pharm Inds, 3M, Vangard, Sandoz, Bristol Myers Squibb, Superpharm, Lederle, Ivax Pharms, and Mutual Pharm, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for ergoloid mesylates. Two suppliers are listed for this compound.

Summary for Generic Name: ergoloid mesylates

Tradenames:8
Patents:0
Applicants:12
NDAs:34
Drug Master File Entries: see list4
Suppliers / Packaging: see list2
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ivax Pharms
HYDROGENATED ERGOT ALKALOIDS
ergoloid mesylates
TABLET;SUBLINGUAL087185-001Approved Prior to Jan 1, 1982DISCNNo► subscribe► subscribe
Kv Pharm
ERGOLOID MESYLATES
ergoloid mesylates
TABLET;SUBLINGUAL086264-001Approved Prior to Jan 1, 1982DISCNNo► subscribe► subscribe
Watson Labs
ERGOLOID MESYLATES
ergoloid mesylates
TABLET;SUBLINGUAL084930-001Approved Prior to Jan 1, 1982DISCNNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ergoloid mesylates

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
HYDERGINE LC
ergoloid mesylates
CAPSULE;ORAL018706-001Jan 18, 19834,366,145► subscribe
Novartis
HYDERGINE
ergoloid mesylates
SOLUTION;ORAL018418-001Approved Prior to Jan 1, 19824,138,565► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc